Anemia of Chronic Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Anemia of Chronic Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Anemia of chronic disease (ACD) or anemia of inflammation is a type of anemia that affects people who have conditions that cause inflammation, such as infections, cancer, autoimmune diseases, and chronic kidney disease (CKD). In ACD there is reduced iron levels in the blood. Symptoms includes fast heartbeat, body aches, fainting or feeling dizzy or light-headed, feeling tired or weak, getting tired easily during or after physical activity, pale skin, and shortness of breath. Complete blood count and blood smear can be used for diagnosis. Erythropoiesis-stimulating agents (ESAs) like epoetin alpha or darbepoetin alpha are used to treat anemia related to CKD, chemotherapy treatments for cancer, or certain treatments for HIV. Blood transfusions may be used in severe anemia.
The Anemia of Chronic Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Anemia of Chronic Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anemia of Chronic Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Anemia of Chronic Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Anemia of Chronic Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Anemia of Chronic Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Anemia of Chronic Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Anemia of Chronic Disease reports